In the early days of the pandemic, if there was one coronavirus vaccine stock investors were betting on, it was Novavax (NASDAQ: NVAX). The biotech stock soared more than 2,700% in 2020 as it developed its vaccine candidate. In the same timeframe, Pfizer shares hardly budged.
It may be a bit early to establish Moderna's (NASDAQ: MRNA) and Teladoc Health's (NYSE: TDOC) lasting growth stock status by looking at the past couple of years. Moderna launched the coronavirus vaccine as its first product in 2020 -- and vaccinated a good share of the population. Teladoc saw revenue and virtual medical visits soar in the triple digits as people opted to stick close to home.
Health reporter Anjalee Khemlani examines the shortages Moderna is experiencing in its latest COVID-19 booster shot, while also discussing vaccination options ahead of this year's flu season